1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 22 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2010Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatmentKim, D.; Kim, D.; Kim, S.; Goh, H.; Pane, F.; Hughes, T.; Radich, J.; Lin, P.; Saglio, G.; Branford, S.; Martinelli, G.; Soverini, S.; Hochhaus, A.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be AppropriateBranford, S.; Goh, H.; Izzo, B.; Beppu, L.; Ortmann, C.; Duniec, K.; Jin, Y.; Woodman, R.; Pane, F.; Kim, D.; Radich, J.; Hughes, T.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2016Chronic myeloid leukemia: reminiscences and dreamsMughal, T.; Radich, J.; Deininger, M.; Apperley, J.; Hughes, T.; Harrison, C.; Gambacorti-Passerini, C.; Saglio, G.; Cortes, J.; Daley, G.
2013Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaStein, A.; Martinelli, G.; Hughes, T.; Muller, M.; Beppu, L.; Gottardi, E.; Branford, S.; Soverini, S.; Woodman, R.; Hochhaus, A.; Kim, D.; Saglio, G.; Radich, J.
2008Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiale Coutre, P.; Ottmann, O.; Giles, F.; Kim, D.; Cortes, J.; Gattermann, N.; Apperley, J.; Larson, R.; Abruzzese, E.; O'Brien, S.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F.; Saglio, G.; Gobbi, M.; Kwong, Y.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J.; et al.
2013Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapyAngelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
2009Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaHochhaus, A.; O'Brien, S.; Guilhot, F.; Druker, B.; Branford, S.; Foroni, L.; Goldman, J.; Muller, M.; Radich, J.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T.; Larson, R.
2009Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive valueHochhaus, A.; Muller, M.; Radich, J.; Branford, S.; Kantarjian, H.; Hanfstein, B.; Rousselot, P.; Kim, D.; Lipton, J.; Bleickhardt, E.; Lambert, A.; Hughes, T.
2006Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemiaBranford, S.; Cross, N.; Hochhaus, A.; Radich, J.; Saglio, G.; Kaeda, J.; Goldman, J.; Hughes, T.
2003Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaHughes, T.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M.; Gathmann, I.; Bolton, A.; van Hoomissen, I.; Goldman, J.; Radich, J.

Discover